Sean Grant - 15 Jun 2021 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Chief Financial Officer
Signature
/s/ Jodie Bourdet, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
15 Jun 2021
Net transactions value
+$68,004
Form type
4
Filing time
16 Jun 2022, 16:06:32 UTC
Next filing
15 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Purchase $38,300 +2,816 $13.60 2,816 15 Jun 2022 By IRA F1
transaction VERA Class A Common Stock Purchase $4,556 +335 $13.60 335 15 Jun 2022 By Roth IRA F1
transaction VERA Class A Common Stock Purchase $11,656 +857 $13.60 857 15 Jun 2022 By Spouse's IRA F1
transaction VERA Class A Common Stock Purchase $13,492 +992 $13.60 992 15 Jun 2022 By Trust F1
holding VERA Class A Common Stock 1,518 15 Jun 2021 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were purchased in multiple transactions for all of Reporting Person's indirect accounts on the reported date with prices ranging from $13.05 to $13.85, resulting in a weighted average price of $13.6008. Upon request, the Reporting Person will provide to Issuer, the Commission staff or a security holder of the Issuer the number of shares purchased and the purchase price for each separate transaction.
F2 Shares acquired under the Issuer's Employee Stock Purchase Plan on March 11, 2022.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney